Nowadays, we have established the optimal protocol for anti-IL-2 agonistic antibody development services to meet the requirement of our worldwide customers. For instance, many anti-IL-2 agonistic antibodies have been generated by using other immune checkpoint inhibitors, such as PD-1/PD-L1 antibody, anti-CTLA-4 antibody. The results illustrate that these antibodies are effective in treating various types of cancer cells and enhancing anti-tumor potency in anim